PHARMACOKINETICS OF CITALOPRAM IN RELATION TO GENETIC POLYMORPHISM OF CYP2C19

References

Page 1

	Year	Citations
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. S.M. de Morais, G. Wilkinson, Joyce Blaisdell, Journal of Biological Chemistry	1994	952
Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Sara Moráis, G. Wilkinson, Joyce Blaisdell, Molecular Pharmacology	1994	750
Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin Leif Bertilsson, Ya‐Qing Lou, Yun-Long Du, Clinical Pharmacology & Therapeutics BiologyPronounced DifferencesChinese SubjectsChinese Extensive MetabolizersSwedish Populations	1992	403
Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man A. K�pfer, R Preisig European Journal of Clinical Pharmacology PharmacologyPharmacogenomicsMedicine	1984	363
Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. Paul B. Watkins, Scott A Murray, L G Winkelman, Journal of Clinical Investigation PharmacotherapyExperimental PharmacologyPhysiologically-based Pharmacokinetic ModelingOxidative StressP-450iiia Inducers Dexamethasone	1989	351
Debrisoquine/Sparteine Hydroxylation Genotype and Phenotype: Analysis of Common Mutations and Alleles of <i>CYP2D6</i> in a European Population Franck Broly, Andrea Gaedigk, Markus H. Heim, DNA and Cell Biology	1991	223
Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese Yukio Horai, Masayuki Nakano, Takashi Ishizaki, Clinical Pharmacology & Therapeutics	1989	219
Pneumoconiosis. A histological survey of necropsy material in 1205 cases. Gloyne PubMed Necropsy MaterialGross AnatomyPneumothorax	1951	217
Pharmacokinetics of Citalopram in Relation to the Sparteine and the Mephenytoin Oxidation Polymorphisms Søren H. Sindrup, Kim Brøsen, M. G. J. Hansen, Therapeutic Drug Monitoring PharmacotherapyDrug ResistanceMedicinal ChemistryPharmacological StudyToxicology	1993	215
A New Genetic Defect in Human CYP2C19: Mutation of the Initiation Codon Is Responsible for Poor Metabolism of S-Mephenytoin Ronald J. Ferguson, Sonia M. F. de Morais, Simone Benhamou, Journal of Pharmacology and Experimental Therapeutics	1998	199

Page 1